Strides Arcolab’s wholly owned subsidiary, Onco Therapies Limited has received final ANDA approval for Vinorelbine Injection USP, 10 mg/mL packaged in 10 mg/1 mL and 50 mg / 5mL single-dose vials.

Vinorelbine is part of the Oncology portfolio licenced to Pfizer for the US market and the product is available for immediate launch.

Vinorelbine is used to treat various types of cancer. It is a chemotherapy drug that works by slowing or stopping cancer cell growth.

Agila Specialties, business of Strides Arcolab is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from nine world-class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. The company’s marketing network covers 70 countries and it has partnerships with some of the world’s leading pharmaceutical companies for both developed and emerging markets.